Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.
نویسندگان
چکیده
OBJECTIVE To evaluate the efficacy and safety of mitoxantrone hydrochloride and determine how it exhibits a differential inhibitory effect on subsets of B cells in patients with highly relapsing neuromyelitis optica (NMO). DESIGN Retrospective case series with prospective follow-up. SETTING Three referral medical centers in the Republic of Korea. PATIENTS Twenty patients with highly relapsing NMO or neuromyelitis optica spectrum disorder who had at least 2 relapses during the year preceding the start of mitoxantrone treatment, despite other immunotherapies. INTERVENTION Infusions of mitoxantrone up to a maximum cumulative dose of 120 mg/m(2). MAIN OUTCOME MEASURES Annualized relapse rate, disability according to the Expanded Disability Status Scale score, and fraction of CD27(+)CD19(+) memory B cells. RESULTS During mitoxantrone treatment, the median annualized relapse rate was reduced by 75%, and 50% of patients became relapse free. Disability improved or stabilized in all patients. No patients had serious adverse effects during the mean follow-up period of 41 months after completing therapy. Flow cytometric analysis of cell surface markers revealed that mitoxantrone treatment preferentially affected CD27(+)CD19(+) memory B cells. CONCLUSIONS Treatment with mitoxantrone in patients with highly relapsing NMO significantly reduces relapse rates, resulting in subsequent functional stabilization or improvement.
منابع مشابه
Efficacy and Safety of Rituximab in patients with Neuromyelitis Optica Spectrum Disorders: A prospective observation in Iranian Cases.
متن کامل
Neuromyelitis Optica in Children: A Rare Entity
Neuromyelitis optica (also known as Devic's disease or Devic's syndrome) is an uncommon disorder in pediatric age group, and is characterized by acute or subacute optic neuritis and transverse myelitis. Here we report an 11- year- old female child with relapsing Neuromyelitis optica (NMO) confirmed by positive NMO- IgG antibody and had clinical recovery with high dose methyl prednisolone t...
متن کاملRepeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
OBJECTIVE To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO). DESIGN Prospective open-label study. SETTING Institutional referral center for multiple sclerosis. Patients Thirty patients with relapsing NMO or NMO spectrum disorder. Interventio...
متن کاملTreatment of neuromyelitis optica: an evidence based review.
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterized by severe optic neuritis and transverse myelitis, usually with a relapsing course. Aquaporin-4 antibody is positive in a high percentage of NMO patients and it is directed against this water channel richly expressed on foot processes of astrocytes. Due to the severity of NMO attacks and the high ri...
متن کاملNeuromyelitis optica presenting with relapses under treatment with natalizumab: a case report
INTRODUCTION Neuromyelitis optica is an inflammatory demyelinating disease of the central nervous system. To date, optimal therapeutic approaches for neuromyelitis optica have yet to be defined. Natalizumab is highly effective in relapsing-remitting multiple sclerosis and might be considered as an option. CASE PRESENTATION Here, we describe a 67-year-old Caucasian man with definite neuromyeli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Archives of neurology
دوره 68 4 شماره
صفحات -
تاریخ انتشار 2011